Myriad Genetics Stock Soars 30.49% on Strong Q2 Earnings

Myriad Genetics' stock surged 30.49% in pre-market trading on August 6, 2025, marking a significant rise in investor confidence.

Myriad Genetics reported strong second-quarter financial results, with revenue reaching $213.1 million, a 1% year-over-year increase. The company also slightly raised its full-year revenue guidance to $823 million from the previous $815 million, reflecting a positive outlook for the remainder of the year.

This strong performance is attributed to the company's strategic initiatives and operational efficiencies, which have helped mitigate previously discussed headwinds. The company's ability to exceed estimates and lift revenue guidance has bolstered investor sentiment, contributing to the stock's pre-market surge.